A Phase 1, Open-label, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of Orally Administered (+)-Epicatechin in Patients With Becker or Becker-like Muscular Dystrophy With Continued Ambulation Past 16 Years of Age
Latest Information Update: 25 Mar 2022
At a glance
- Drugs Epicatechin (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors Epirium Bio
Most Recent Events
- 22 Mar 2022 Status changed from active, no longer recruiting to completed.
- 08 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 12 Aug 2020 According to an Epirium Bio media release, the company announced recruitment of first patient in this study.